HOTH News and Press, Hoth Therapeutics Inc. From 10/05/23

Hoth Therapeutics Announces Merveille.ai Artificial intelligence Initiative for Drug Discovery PR Newswire The new wholly owned subsidiary will screen for rare disease therapeutics. NEW YORK , Oct. 5, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NAS...

FDA Grants Hoth Therapeutics Pre-IND Meeting for HT-KIT, Treatment for Cancer Patients PR Newswire NEW YORK , Oct. 2, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the Pre-IND m...

Hoth Therapeutics Announces Closing of $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules PR Newswire NEW YORK , Sept. 15, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) ("Hoth" or the "Company"), a patient-focused bioph...

2023-09-14 08:35:01 ET Losers: BIOLASE ( BIOL ) -44% on prices $4.5M stock offering . Bionomics Limited ( BNOX ) -20% announces update on the α7 Nicotinic Acetylcholine Receptor positive allosteric modulator collaboration with MSD. Simpple ( SP...

2023-09-13 14:31:04 ET More on Hoth Therapeutics Seeking Alpha’s Quant Rating on Hoth Therapeutics Historical earnings data for Hoth Therapeutics Financial information for Hoth Therapeutics For further details see: Hoth stock tumbles on $2.9M direc...

2023-09-13 14:16:14 ET Gainers: Avalo Therapeutics ( AVTX ) +56% . ZyVersa Therapeutics ( ZVSA ) +41% . Rocket Pharmaceutical ( RCKT ) +35% . Vigil Neuroscience ( VIGL ) +31% . Aspira Women's Health ( AWH ) +27% . Novo Integr...

Hoth Therapeutics Announces $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules PR Newswire NEW YORK , Sept. 13, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced...

2023-09-13 10:18:38 ET DENVER, Colo., Sept 13, 2023 ( www.247marketnews.com)- News Rocket Pharmaceuticals Reaches FDA Alignment on Pivotal Phase 2 Trial Design for RP-A501 in Danon Disease AND Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock ...

Hoth Therapeutics Announces Positive Results Killing Cancer Cells in Both Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia PR Newswire Gastrointestinal Stromal Tumors Cells Rapidly Died Between 48 and 72 Hours After Exposure to HT-KIT. HT-KIT Shows Posit...

Hoth Therapeutics Announces FDA Accepts Pre-Investigational New Drug (Pre-IND) Submission for HT-KIT, Treatment for Cancer Patients PR Newswire HT-KIT received Orphan Drug Designation from FDA for its mRNA Frame Shifting Cancer Therapeutic Hoth intends to initially...